CoChat

The DOI matches its Crossref record; 299 of the 299 references it cites were found in a registry or an index.

Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review

Open access
Christodoulou, Ioannis, Goulielmaki, Maria, Devetzi, Marina, Panagiotidis, Mihalis, Koliakos, Georgios, Zoumpourlis, Vassilis · 2018 · Stem Cell Research & Therapy

Abstract

Mesenchymal stem cells (MSC) comprise a heterogeneous population of rapidly proliferating cells that can be isolated from adult (e.g., bone marrow, adipose tissue) as well as fetal (e.g., umbilical cord) tissues (termed bone marrow (BM)-, adipose tissue (AT)-, and umbilical cord (UC)-MSC, respectively) and are capable of differentiation into a wide range of non-hematopoietic cell types. An additional, unique attribute of MSC is their ability to home to tumor sites and to interact with the local supportive microenvironment which rapidly conceptualized into MSC-based experimental cancer cytotherapy at the turn of the century. Towards this purpose, both naïve (unmodified) and genetically modified MSC (GM-MSC; used as delivery vehicles for the controlled expression and release of antitumorigenic molecules) have been employed using well-established in vitro and in vivo cancer models, albeit with variable success. The first approach is hampered by contradictory findings regarding the effects of naïve MSC of different origins on tumor growth and metastasis, largely attributed to inherent biological heterogeneity of MSC as well as experimental discrepancies. In the second case, although the anti-cancer effect of GM-MSC is markedly improved over that of naïve cells, it is yet apparent that some protocols are more efficient against some types of cancer than others. Regardless, in order to maximize therapeutic consistency and efficacy, a deeper understanding of the complex interaction between MSC and the tumor microenvironment is required, as well as examination of the role of key experimental parameters in shaping the final cytotherapy outcome. This systematic review represents, to the best of our knowledge, the first thorough evaluation of the impact of experimental anti-cancer therapies based on MSC of human origin (with special focus on human BM-/AT-/UC-MSC). Importantly, we dissect the commonalities and differences as well as address the shortcomings of work accumulated over the last two decades and discuss how this information can serve as a guide map for optimal experimental design implementation ultimately aiding the effective transition into clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13287-018-1078-8

Cites

299 of 299 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Mechanisms of MSC homing to tumor sites. Binding of monocyte chemotactic protein-1 (MCP-1 or CCL2), secreted by breast cancer cells or of stromal cell-derived factor 1 (SDF-1) secreted by breast, colon, and prostate cancer cells, on their receptors expressed on MSC surface can modulate the tropism of MSC to tumor sites. Matrix metalloproteinase 1 (MMP-1), localized in the extracellular matrix (ECM), stimulates MSC homing through cleavage and subsequent activation of the G-protein protease-activated receptor (PAR)-1. In correspondence with the homing process of MSC to sites of injury, the interaction between integrin α4/β1 on MSC and its binding site on fibronectin of the ECM plays a major role in the transmigration of MSC into the extracellular matrix. Finally, MSC recruitment can also be achieved through interaction of VEGF, secreted by cancer cells, with its receptor on MSC. After incorporating in tumor site, MSC in turn secrete various pro-angiogenic factors, such as VEGF, fibroblast-derived growth factor, PDGF, and SDF-1 that facilitate angiogenesis
Fig. 1 Mechanisms of MSC homing to tumor sites. Binding of monocyte chemotactic protein-1 (MCP-1 or CCL2), secreted by breast cancer cells or of stromal cell-derived factor 1 (SDF-1) secreted by breast, colon, and prostate cancer cells, on their receptors expressed on MSC surface can modulate the tropism of MSC to tumor sites. Matrix metalloproteinase 1 (MMP-1), localized in the extracellular matrix (ECM), stimulates MSC homing through cleavage and subsequent activation of the G-protein protease-activated receptor (PAR)-1. In correspondence with the homing process of MSC to sites of injury, the interaction between integrin α4/β1 on MSC and its binding site on fibronectin of the ECM plays a major role in the transmigration of MSC into the extracellular matrix. Finally, MSC recruitment can also be achieved through interaction of VEGF, secreted by cancer cells, with its receptor on MSC. After incorporating in tumor site, MSC in turn secrete various pro-angiogenic factors, such as VEGF, fibroblast-derived growth factor, PDGF, and SDF-1 that facilitate angiogenesisCC BY · PubMed Central
Fig. 2 Representation of common cancer types in MSC-based cytotherapy studies compiled in this review in comparison to global cancer incidences (clinical relevance). The most frequently targeted tumors in cancer cytotherapy studies have been ranked in descending order of worldwide cancer incidence (2012 data) [122] from left to right on the x axis. Global cancer incidence rates are depicted as solid line symbols (boxed values), while the frequencies of tumors targeted by unmodified/naïve MSC (n-MSC) or genetically modified MSC (GM-MSC; see also the “Genetically modified MSC as delivery vehicles for antitumorigenic molecules—overview and meta-analysis results” section) in experimental cancer cytotherapy (CT), as determined by our meta-analysis, are represented by black (n-MSC CT) or white (GM-MSC CT) columns, respectively. Sample sizes: N = 79/N = 67 for n-MSC- and GM-MSC-based work, respectively. For each cancer type, the difference in height between the solid line symbols and the column bars denotes the divergence in representation of global cancer incidence by CT work, with positive differences (global % > MSC CT %) signifying under-representation, and negative ones (MSC CT % > global %) over-representation of cancer incidence. For example, the two most under-represented tumors targeted by n-MSC CT are those of lung as well of liver/stomach/pancreas (HGP) (by 12.3% and 8.5%, respectively), while the most over-represented ones are those of breast and brain (difference of − 11.3 and − 8.3, respectively), see the main text (the “Relevance of preclinical cancer cytotherapy targeting to global cancer incidence” section) for further discussion. Overall, the data suggest that in order for experimental CT work to become more clinically relevant, more focus should be put on the following, under-represented tumor targets: * Hepatic/gastric/pancreatic (HGP) tumors (using both n-MSC and GM-MSC). * n-MSC-based lung cancer cytotherapy. * Colorectal cancer targeted by both n-MSC (especially UC-MSC) and GM-MSC. * Prostate cancer targeted by GM-MSC (especially UC-MSC), as well as n-MSC. * GM-UC-MSC-based brain tumor cytotherapy
Fig. 2 Representation of common cancer types in MSC-based cytotherapy studies compiled in this review in comparison to global cancer incidences (clinical relevance). The most frequently targeted tumors in cancer cytotherapy studies have been ranked in descending order of worldwide cancer incidence (2012 data) [122] from left to right on the x axis. Global cancer incidence rates are depicted as solid line symbols (boxed values), while the frequencies of tumors targeted by unmodified/naïve MSC (n-MSC) or genetically modified MSC (GM-MSC; see also the “Genetically modified MSC as delivery vehicles for antitumorigenic molecules—overview and meta-analysis results” section) in experimental cancer cytotherapy (CT), as determined by our meta-analysis, are represented by black (n-MSC CT) or white (GM-MSC CT) columns, respectively. Sample sizes: N = 79/N = 67 for n-MSC- and GM-MSC-based work, respectively. For each cancer type, the difference in height between the solid line symbols and the column bars denotes the divergence in representation of global cancer incidence by CT work, with positive differences (global % > MSC CT %) signifying under-representation, and negative ones (MSC CT % > global %) over-representation of cancer incidence. For example, the two most under-represented tumors targeted by n-MSC CT are those of lung as well of liver/stomach/pancreas (HGP) (by 12.3% and 8.5%, respectively), while the most over-represented ones are those of breast and brain (difference of − 11.3 and − 8.3, respectively), see the main text (the “Relevance of preclinical cancer cytotherapy targeting to global cancer incidence” section) for further discussion. Overall, the data suggest that in order for experimental CT work to become more clinically relevant, more focus should be put on the following, under-represented tumor targets: * Hepatic/gastric/pancreatic (HGP) tumors (using both n-MSC and GM-MSC). * n-MSC-based lung cancer cytotherapy. * Colorectal cancer targeted by both n-MSC (especially UC-MSC) and GM-MSC. * Prostate cancer targeted by GM-MSC (especially UC-MSC), as well as n-MSC. * GM-UC-MSC-based brain tumor cytotherapyCC BY · PubMed Central
Fig. 3 Anti-cancer efficiencies of naïve MSC isolated from adult bone marrow (BM), adipose tissue (AT) or fetal umbilical cord (UC). a Radar graph depicting differences in frequencies of UC- (red), BM- (black), or AT-derived (blue) MSC associated with tumor suppressive activity in vivo and/or in vitro. The tumor suppression frequency for each MSC type relative to the other two is represented by vertical distances from graph center. Each outer vertex represents the maximum frequency (100%), equal to the sum of the three relative frequencies of the respective MSC types. Suppression rates are shown for four consolidated groups (presented in ascending order of size clockwise starting from “in vivo”). Values for the highest suppression rate in each of the four groups are shown. b Radar graph depicting differences in frequencies of UC- (red), BM- (black), or AT-derived (blue) MSC with respect to pro-tumorigenic behavior in vivo and/or in vitro. The tumor promotion frequency for each MSC type relative to the other two is represented by vertical distances from graph center. Each outer vertex represents the maximum frequency (100%), equal to the sum of the three relative frequencies of the respective MSC types. Promotion rates are shown for four consolidated groups (presented in ascending order of size clockwise starting from “in vivo”). Highest observed values for each of the groups are shown. c Distribution of pro- vs. antitumorigenic effects for each of the three naïve MSC types in vitro and in vivo (N = 26/46/25 for AT-/BM-/UC-MSC, respectively). In the case of UC-MSC, all pro-tumorigenic effects were observed in vitro
Fig. 3 Anti-cancer efficiencies of naïve MSC isolated from adult bone marrow (BM), adipose tissue (AT) or fetal umbilical cord (UC). a Radar graph depicting differences in frequencies of UC- (red), BM- (black), or AT-derived (blue) MSC associated with tumor suppressive activity in vivo and/or in vitro. The tumor suppression frequency for each MSC type relative to the other two is represented by vertical distances from graph center. Each outer vertex represents the maximum frequency (100%), equal to the sum of the three relative frequencies of the respective MSC types. Suppression rates are shown for four consolidated groups (presented in ascending order of size clockwise starting from “in vivo”). Values for the highest suppression rate in each of the four groups are shown. b Radar graph depicting differences in frequencies of UC- (red), BM- (black), or AT-derived (blue) MSC with respect to pro-tumorigenic behavior in vivo and/or in vitro. The tumor promotion frequency for each MSC type relative to the other two is represented by vertical distances from graph center. Each outer vertex represents the maximum frequency (100%), equal to the sum of the three relative frequencies of the respective MSC types. Promotion rates are shown for four consolidated groups (presented in ascending order of size clockwise starting from “in vivo”). Highest observed values for each of the groups are shown. c Distribution of pro- vs. antitumorigenic effects for each of the three naïve MSC types in vitro and in vivo (N = 26/46/25 for AT-/BM-/UC-MSC, respectively). In the case of UC-MSC, all pro-tumorigenic effects were observed in vitroCC BY · PubMed Central
Fig. 4 Cancer types most frequently associated with naive AT-/BM-/UC-MSC according to the type of anti-cancer effect produced (suppression or promotion) in vitro and in vivo. a The colored central pie chart depicts the distribution of the four most common tumors upon which naïve MSC were found to have a detrimental (onco-suppressive) effect. The percentage of relative association of each MSC type with each of the tumors is represented by the respective gray-scale peripheral pie chart. The type of MSC most frequently associated with its target tissue and the frequency (%) value are highlighted with a white box within the peripheral pie chart. Total sample size = 54 experiments using solely naïve MSC or naïve MSC as controls for GM-MSC-focused work. Only tumor targets with a minimum sample size of seven (N ≥ 7) are shown. b The colored central pie chart depicts the distribution of the three most common tumors associated with a supportive function (tumor promotion) of MSC. The % relative association of each MSC type with each of the tumors is represented by the respective gray-scale peripheral pie chart. The type of MSC most frequently associated with its target tissue and the frequency (%) value are highlighted with a white box within the peripheral pie chart. Total sample size = 50 experiments using solely naïve MSC in addition to naïve MSC used as controls for GM-MSC-focused work. Only tumor targets with a minimum sample size of seven (N ≥ 7) are shown. In the case of colorectal cancer, the absence of UC from the MSC pie is due to the lack of relevant studies, rather than the lack of tumor promotion on the specific target
Fig. 4 Cancer types most frequently associated with naive AT-/BM-/UC-MSC according to the type of anti-cancer effect produced (suppression or promotion) in vitro and in vivo. a The colored central pie chart depicts the distribution of the four most common tumors upon which naïve MSC were found to have a detrimental (onco-suppressive) effect. The percentage of relative association of each MSC type with each of the tumors is represented by the respective gray-scale peripheral pie chart. The type of MSC most frequently associated with its target tissue and the frequency (%) value are highlighted with a white box within the peripheral pie chart. Total sample size = 54 experiments using solely naïve MSC or naïve MSC as controls for GM-MSC-focused work. Only tumor targets with a minimum sample size of seven (N ≥ 7) are shown. b The colored central pie chart depicts the distribution of the three most common tumors associated with a supportive function (tumor promotion) of MSC. The % relative association of each MSC type with each of the tumors is represented by the respective gray-scale peripheral pie chart. The type of MSC most frequently associated with its target tissue and the frequency (%) value are highlighted with a white box within the peripheral pie chart. Total sample size = 50 experiments using solely naïve MSC in addition to naïve MSC used as controls for GM-MSC-focused work. Only tumor targets with a minimum sample size of seven (N ≥ 7) are shown. In the case of colorectal cancer, the absence of UC from the MSC pie is due to the lack of relevant studies, rather than the lack of tumor promotion on the specific targetCC BY · PubMed Central
Fig. 5 Relationship between adoption of experimental model in vivo (animal model) and in vitro (culture format) and outcome of naïve MSC-based cancer cytotherapy experiments. a In vivo. Bar of pie chart categories denote relative contribution of MSCs to the most frequently observed outcome for each animal model. Naïve MSC plus naïve MSC used as controls for GM-MSC-focused work were used to derive total sample size. For experiments on athymic- nude mice, N = 30. For experiments on SCID mice, N = 17. b In vitro. Co-C = direct or indirect co-culture of naïve MSC with cancer cells. C.Med = use of naïve MSC-conditioned media on cancer cells. Sample sizes: N = 23/29/29, for AT-/BM-/UC-MSC, respectively
Fig. 5 Relationship between adoption of experimental model in vivo (animal model) and in vitro (culture format) and outcome of naïve MSC-based cancer cytotherapy experiments. a In vivo. Bar of pie chart categories denote relative contribution of MSCs to the most frequently observed outcome for each animal model. Naïve MSC plus naïve MSC used as controls for GM-MSC-focused work were used to derive total sample size. For experiments on athymic- nude mice, N = 30. For experiments on SCID mice, N = 17. b In vitro. Co-C = direct or indirect co-culture of naïve MSC with cancer cells. C.Med = use of naïve MSC-conditioned media on cancer cells. Sample sizes: N = 23/29/29, for AT-/BM-/UC-MSC, respectivelyCC BY · PubMed Central
Fig. 6 Tumor suppression rates (%) for genetically modified MSC (GM-MSC) in comparison to naïve MSC (n-MSC) and non-MSC controls. Tumor suppression rates were determined using measured experimental outcomes (e.g., tumor size and weight, animal survival rate, proliferation assays) derived from 20 selected publications in which the anti-cancer efficacy of genetically modified human MSC was directly compared to that of unmodified, naïve MSC and non-MSC controls. a Whisker plots. Values next to whisker boxes depict median values. b Tabular summary of the data plotted in a. Sample size (N) relates to total number of experimental readouts (e.g., tumor size and weight, animal survival rate, proliferation assays) based on which % tumor suppression was calculated. P values correspond to t tests comparing the specific groups
Fig. 6 Tumor suppression rates (%) for genetically modified MSC (GM-MSC) in comparison to naïve MSC (n-MSC) and non-MSC controls. Tumor suppression rates were determined using measured experimental outcomes (e.g., tumor size and weight, animal survival rate, proliferation assays) derived from 20 selected publications in which the anti-cancer efficacy of genetically modified human MSC was directly compared to that of unmodified, naïve MSC and non-MSC controls. a Whisker plots. Values next to whisker boxes depict median values. b Tabular summary of the data plotted in a. Sample size (N) relates to total number of experimental readouts (e.g., tumor size and weight, animal survival rate, proliferation assays) based on which % tumor suppression was calculated. P values correspond to t tests comparing the specific groupsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Show all 299 references

Research works printed but not linked: 1

  1. Moinfar F, Man YG, Bratthauer GL, Ratschek M, Tavassoli FA. Genetic abnormalities in mammary ductal intraepithelial neoplasia-flat type (“clinging ductal carcinoma in situ”). Cancer. 2000;88:2072–81. · doi:10.1002/(sici)1097-0142(20000501)88:9<2072::aid-cncr13>3.0.co;2-h

Cited by

See all 122

Metadata

Authors
Christodoulou, I., Goulielmaki, M., Devetzi, M., Panagiotidis, M., Koliakos, G., & Zoumpourlis, V.
Affiliations
National Hellenic Research Foundation (GR)
Corresponding author
Zoumpourlis, Vassilis
Venue
Stem Cell Research & Therapy
Published
2018-12
Volume
9
Issue
1
Pages
336-336
ISSN
1757-6512 (ISSN-L)
OpenAlex
W2904058752
Cited by
122
References
299
Citations by year
2026: 8 · 2025: 11 · 2024: 19 · 2023: 21 · 2022: 18 · 2021: 16 · 2020: 18 · 2019: 10 · 2018: 1
FWCI
1.63
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0/ (tdm)
Locations
  • Stem Cell Research & Therapy (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Northumbria Research Link (Northumbria University) (acceptedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • National Hellenic Research Foundation Helios Repository (National Hellenic Research Foundation) (submittedVersion)
Funders
  • General Secretariat for Research and Technology (2400)
  • State Scholarships Foundation
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
mesenchymal stem cells, bone marrow-derived mesenchymal stem cells, adipose-derived stem cells, human umbilical cord mesenchymal stem cells, tumor microenvironment, tumor growth, metastasis, preclinical cancer models, experimental design
MeSH terms
Animals, Humans, Neoplasms, Phenotype, Mesenchymal Stem Cell Transplantation, Tumor Microenvironment, Mesenchymal Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review. https://app.cochat.ai/papers/10.1186/s13287-018-1078-8
The paper
Christodoulou, I., Goulielmaki, M., Devetzi, M., Panagiotidis, M., Koliakos, G., & Zoumpourlis, V. (2018). Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review. Stem Cell Research & Therapy. https://doi.org/10.1186/s13287-018-1078-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.